A globally-renowned prostate cancer surgeon shares the latest advancements in the field and stresses the importance of early ...

Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...

The “striking” findings showed an overall upward trend in life expectancy when patients took niraparib - a targeted therapy ...

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL ...

Adding the drug enzalutamide to standard hormone therapy reduced the risk of premature death by more than 40% in patients ...

A silent killer that is the second leading cause of death among American men, prostate cancer is a disease that has recently come to the forefront of medical research. Studies and new reviews are ...

Targeted prostate checks would save lives at a cost of just £18 per head, research has found. Experts said offering tests to men at most risk would prevent thousands of deaths, amounting to more than ...

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in Cell show that the Decipher Prostate Genomic ...

Prostate cancer blood tests can lead to men being over-tested, while those who need help may be missed, a large study has ...

Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit ...

With the backing of Rishi Sunak, Prostate Cancer UK published a report to the national screening committee back in 2022 in ...